MedTrace Logo

A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

NCT01298310 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-05-22

No results posted yet for this study

Summary

To characterize the phenotype in patients with Morton's neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Conditions

  • Morton's Neuroma

Interventions

DRUG

Xylocaine

1 mg/mL solution for injection

DRUG

Xylocaine

10 mg/mL solution for injection

DRUG

Placebo

solution for injection

Sponsors & Collaborators

Principal Investigators

  • Bror Jonzon, MD, PhD · AstraZeneca R&D Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298310 on ClinicalTrials.gov